Stereotaxis, Inc. (STXS)
Pre-market:
| Previous close | 2.5600 |
| Open | 2.6100 |
| Bid | 2.2500 x 900 |
| Ask | 3.2500 x 1000 |
| Day's range | 2.3800 - 2.6100 |
| 52-week range | 1.3300 - 3.2900 |
| Volume | |
| Avg. volume | 310,745 |
| Market cap | 195.467M |
| Beta (5Y monthly) | 1.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2700 |
| Earnings date | 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.60 |
GlobeNewswireStereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 first quarter on Monday, May 13, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments. What: Stereotaxis first quarter 2024 fin
ZacksStereotaxis (STXS) Seeks Clearance for MAGiC Catheter
Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.
Insider MonkeyStereotaxis, Inc. (AMEX:STXS) Q4 2023 Earnings Call Transcript
Stereotaxis, Inc. (AMEX:STXS) Q4 2023 Earnings Call Transcript March 4, 2024 Stereotaxis, Inc. reports earnings inline with expectations. Reported EPS is $-0.07 EPS, expectations were $-0.07. STXS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. Thank you for […]
